Vical Incorporated expects to announce top-line data mid-2013 from the pivotal Phase III trial of Allovectin in metastatic melanoma, some two years later than first predicted.
http://seekingalpha.com/article/1399261-undervaluation-of-vical-s-full-pipeline-allows-a-cheap-bet-on-cancer-trial?source=feed
http://seekingalpha.com/article/1399261-undervaluation-of-vical-s-full-pipeline-allows-a-cheap-bet-on-cancer-trial?source=feed
No comments:
Post a Comment